Science Highlights
Published on July 30, 2025
Safety and efficacy of brexu-cel in relapsed/refractory CNS B-ALL
by Blood Advances
Muhsen IN, Roloff GW, Faramand RG, et al. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood Advances. 2025; (doi: 10.1182/bloodadvances.2024015779).
A retrospective analysis shows brexucabtagene autoleucel (brexu-cel), a chimeric antigen receptor (CAR) T-cell therapy, is safe and effective for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system (CNS) involvement. This patient subgroup, notorious for unfavorable outcomes, historically has not qualified for participation in clinical trials evaluating CD19-directed CAR T. However, data from the Real-World Outcomes Collaborative for CAR T in ALL confirms high response rates in B-ALL patients with CNS-2 or CNS-3 disease who undergo brexu-cel infusion. Importantly, brexu-cel achieves this result with no more toxicity than observed in B-ALL patients with no CNS involvement.
Read More
![]()